The model has shifted from a course to continuing care
For many years, people treated weight medicines like an antibiotic: a course with a start and an end, after which the result was expected to last. The scientific update says something different. The US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) explains that obesity is a chronic disease, that most weight-management medicines approved today are intended for long-term use, and that a clinician may advise continuing them indefinitely while they help and do not cause serious side effects [1].
The NHS page on obesity treatment and a JAMA review of obesity management make the same point: medicine is part of a chronic-care plan, not a temporary fix separate from eating, movement, sleep and behavioural support [9, 14]. A 2026 joint guidance statement from US obesity societies also treats drug therapy as an ongoing decision that is reviewed at intervals [10].
So treatment length is not set by an empty pen or a passed occasion. It depends on the health benefit achieved, tolerance, general health, the available alternatives, and your own choice once you understand the full picture [1, 10]. If you want to understand how these medicines work in the first place, read the GLP-1 medication guide on the site.
What happens when the medicine stops? What the trials show
Two important trials answer this question with numbers. In the STEP 1 extension, people who stopped semaglutide after 68 weeks of treatment regained about two-thirds of the weight they had lost within one year of stopping. Most of the improvements in blood pressure, glucose and lipids also drifted back towards baseline [5].
In the SURMOUNT-4 trial, participants took tirzepatide for 36 weeks and lost on average about 20.9% of their body weight. They were then randomised: those who continued the medicine lost a further 5.5%, while those switched to placebo regained about 14% of their weight over 52 weeks [6]. A later analysis of the same trial found that most people who stopped regained a quarter or more of the weight they had lost, and that cardiometabolic improvements lessened as weight returned [7].
It is important to read this correctly. This regain does not prove that treatment failed or that the person lacks willpower. It reflects the fact that the medicine influences hunger and fullness signals while it is present, and when it is removed the body tends to defend its previous weight [1, 6]. That is why NIDDK states plainly that some weight regain after stopping is expected for many people [1].
When is the plan reviewed, and who decides on continuing?
Guidelines set clear review points so that continuing is not automatic. NIDDK says that if a person has not lost at least 5% of their starting weight after 12 weeks on the full dose, the clinician will probably suggest stopping the medicine or changing the plan [1]. In its recommendation on tirzepatide, NICE says that if less than 5% of initial weight has been lost after 6 months on the highest tolerated dose, the decision to continue should weigh the benefits and risks for that person [3].
Some health systems also set time limits for organisational reasons. The NICE recommendation on semaglutide in the UK health service set a maximum of 2 years, within a specialist multidisciplinary weight-management service [2]. That limit is a decision for a particular health system, not evidence that the body is free of the disease after two years, which is why a plan for after stopping should be made early [2, 5].
Review asks practical questions: has the medicine produced a health benefit, not only a number on the scale? Are food, protein and fluids adequate? Have side effects appeared? Is there a planned pregnancy, a new illness or a new medicine that changes the decision? [1, 4]. These answers decide whether to continue, adjust or step down.
Side effects and safety while continuing
The most common side effects with GLP-1 medicines and tirzepatide are digestive: nausea, diarrhoea, constipation and vomiting, usually most noticeable when starting or increasing the dose. In the lead-in phase of SURMOUNT-4, for example, nausea affected about 35.5% of participants [6]. If this is your problem, the article on nausea and constipation with injections explains practical steps and when to contact your clinician.
There are also important precautions your clinician should know about before starting and while continuing. MedlinePlus asks that the clinician be told about any history of pancreatitis, diabetic retinopathy or severe stomach problems [13]. The NHS explains that semaglutide is not used during pregnancy and that anyone planning a pregnancy should stop it at least 2 months beforehand [11]. For tirzepatide, the NHS advises additional barrier contraception for 4 weeks after starting and after each dose increase [12]. This planning is covered in the article on weight medicines before pregnancy.
The basic rule: do not stop, restart or change a dose on your own. Agree with your clinician on the signs that need prompt contact, such as persistent severe abdominal pain, vomiting that stops you drinking, or signs of dehydration [11, 13].
Food and muscle during long-term treatment
When appetite is reduced for a long time, the risk is not only in how much weight is lost but also in the quality of what is eaten. A post hoc analysis of the SURMOUNT trials found that adverse events related to malnutrition were uncommon, but the researchers noted that the trials did not routinely measure vitamin and mineral levels, which limits conclusions about nutritional safety [8].
The practical plan therefore focuses on enough protein at each meal, vegetables, fruit and fibre, adequate fluids especially when there is vomiting or diarrhoea, and blood tests reviewed according to the situation [8, 9]. NIDDK notes that federal physical activity guidelines recommend at least 150 minutes a week of moderate activity and at least 2 days a week of muscle-strengthening activity [1].
Protecting muscle matters because part of the weight lost may be muscle, and muscle makes a difference to strength, mobility and later weight stability. The article on protecting muscle while losing weight explains the role of protein and resistance exercise in more detail [1, 9].
Plan stopping and maintenance before the last dose
If stopping is decided, whether because of a planned pregnancy, side effects, personal choice or medicine availability, the plan is best discussed before the last dose, not after weight starts to return [1, 5]. It may include closer follow-up in the first months, monitoring weight and waist size, and consolidating the eating, activity and sleep habits built during treatment [1, 14].
NIDDK explains that keeping healthy eating habits and increasing physical activity may help people regain less weight or keep it off [1]. In some cases the clinician may discuss other options, such as a different medicine or a lower dose, or revisit wider choices in line with NICE guidance on medicines and surgery [4].
What matters is that any regain is met with a calm review, not with blame. The goal remains health: blood pressure, glucose, liver, joints and mobility, as explained in the article on obesity care beyond BMI [4, 14].
Leave the visit with a clear next step
Before starting a weight medicine or deciding to stop one, ask specific questions: what is the health goal? When will we review the response? What happens if I do not lose the expected weight? And if I stop, what is the follow-up plan? These answers make the decision shared and informed [1, 10].
Bring a list of all medicines and supplements you take, any history of pancreatic, gallbladder or family thyroid disease, and pregnancy plans if any, because all of these affect choice and safety [11, 13]. If this is your first visit to a weight clinic, the guide to a first weight-management visit explains the measurements and questions to expect.
If you need an individual review of your medicine plan or your stopping and maintenance plan, you can book an appointment at the clinic. This is a practical next step, not a promised result, and the treating team will decide what suits your situation after assessment [1, 4].
